Lyfegen Secures CHF 5 Million in Series A
Lyfegen, a Basel, Switzerland-based healthtech company specializing in drug rebate management, has raised an additional CHF 5 million in a Series A funding round.
Lyfegen, a Basel, Switzerland-based healthtech company specializing in drug rebate management, has raised an additional CHF 5 million in a Series A funding round.
Investors
The round was led by TX Ventures with participation from aMoon and other institutional investors.
TX Ventures is a venture capital fund that invests predominantly in B2B Fintech across Europe – preferably in the seed to series A stage.
Lyfegen Use of Funds
The company will use the funds to scale its drug rebate management platform globally.
About Lyfegen
Founded in 2018, Lyfegen provides rebate management software designed for the healthcare industry. Lyfegen solutions are used by health insurance, governments, hospital payers, and pharmaceutical companies around the globe to dramatically reduce the administrative burden of managing complex drug pricing agreements and to optimize rebates and get better value from those agreements. Headquartered in Basel, Switzerland, the company has a market presence in Europe, North America, and the Middle East.
Funding Details
Company: Lyfegen HealthTech AG
Raised: CHF 5.0M
Round: Series A
Funding Date: December 2024
Lead Investor: TX Ventures
Additional Investor: aMoon
Company Website: https://www.lyfegen.com/
Software Category: Drug Rebate Management
